Psychoactive Drugs: Classification and History — Study Notes

Key Concepts and Definitions

• Psychoactive drug: a substance that directly alters the functioning of the central nervous system (CNS). The core definition emphasizes direct CNS effects on brain chemistry and function.
• CNS effects underpinning addiction: psychoactive drugs act on primitive (emotional, instinctive) brain circuits and on higher-order regions (e.g., neocortex) that govern reasoning and decision-making.
• Reward/reinforcement circuitry: discovery of the brain's reward system (including the ventral tegmental area, lateral hypothalamus, amygdala, and especially the nucleus accumbens) has helped explain addiction and craving.
• Drugs can be classified in multiple ways (by purpose of use, chemical/trade/street names, and by effects). The notes that follow align with the book’s emphasis on practical and historical classifications.
• Historical context matters: regulation, taxation, and prohibition have shaped how drugs are produced, distributed, and consumed, not just their pharmacology.

Classification by Purpose of Use (and History of Use)

• Ancient examples of medicinal or ritual use as justification for use (Egypt, Peru, China, etc.).
• Examples cited in the text illustrate how substances moved from sacred, ritual, or medical contexts toward broader social use and sometimes abuse.
• In many cases, drugs were used to relieve pain, control illness, or ease fear; over time, social, economic, and political factors shifted their roles.

Classification by Names and Nomenclature

• Chemical names describe molecular structure (e.g., $ext{C}<em>2 ext{H}</em>5 ext{OH}$ for ethanol).
• Trade (brand) names identify pharmaceutical products (e.g., Xanax® for alprazolam; OxyContin® for oxycodone).
• Street names evolve rapidly and can have multiple forms; examples include: marijuana ("chronic", "medibles"), cocaine ("oxidado", "crack"), bath salts (designer stimulants), heroin ("smack").
• The practical takeaway: every psychoactive drug may be known by dozens of informal names, complicating detection and regulation.

Classification by Effects (Major Drug Groups)

• Uppers (stimulants): CNS stimulants that increase alertness, energy, and arousal.
  • Examples: cocaine (hydrochloride, freebase, crack); amphetamines (Adderall, crystal meth, speed); amphetamine congeners (Ritalin, diet pills); plant stimulants (khat, betel nuts, ephedra, yohimbe); caffeine (coffee, tea, colas, chocolate); nicotine (tobacco products); designer stimulants (bath salts); psychostimulants (MDMA/Molly) which can have psychedelic effects at higher doses or in combination with other stimulants.
  • Physical effects (from small to moderate doses): energized muscles, increased alertness, insomnia, tachycardia, hypertension, decreased appetite.
  • Mental/emotional effects: increased confidence, sociability, euphoria or rush depending on the drug and user.
  • Risks: larger doses or prolonged use can cause anxiety, paranoia, cognitive disruption, and in some cases psychosis; chronic use depletes energy chemicals and can exhaust the body.
• Downers (depressants): CNS depressants that slow brain activity and bodily functions.
  • Categories: opiates/opioids (opium, heroin, oxycodone, hydrocodone, buprenorphine, methadone); sedative-hypnotics (benzodiazepines like alprazolam and clonazepam; barbiturates; Z-hypnotics like zolpidem; other sedatives); alcohol; others (antihistamines, muscle relaxants, OTC sedatives).
  • Physical effects: slowed heart rate and respiration, muscle relaxation, impaired coordination, sleep, dulling of senses; high doses risk respiratory depression and overdose.
  • Mental/emotional effects: initial disinhibition (especially alcohol) followed by relaxation, reduced anxiety, potential euphoria; long-term use risks include dependence.
• All Arounders (psychedelics): substances that distort perception and can induce illusions, delusions, or hallucinations.
  • Classifications: indoles (LSD, psilocybin mushrooms); phenylalkylamines (peyote/mescaline, psycho-stimulants like MDMA); anticholinergics (belladonna, datura, mandrake); cannabinoids (marijuana, hashish, synthetics like K2/Spice); others (ketamine, PCP, Salvia divinorum, nutmeg, dextromethorphan, bromo-dragonFLY, lion’s tail, Amanita mushrooms).
  • Physical effects: often not as dominant as mental effects; ketamine and PCP have anesthetic properties; most psychedelics can cause nausea at higher doses and dizziness.
  • Mental/Emotional effects: altered sensory processing, intensified sensations, synesthesia-like experiences, perceptual distortions, possible delirium or hallucinations.
• Inhalants (deliriants): inhaled gaseous or volatile liquids leading to CNS depression and delirium.
  • Examples: organic solvents (glue, butane, gasoline, paints); volatile nitrites (amyl, butyl nitrite); nitrous oxide (laughing gas).
  • Physical effects: dizziness, slurred speech, poor coordination, possible coma or sudden death from respiratory depression; organic solvents can be directly toxic to lungs, brain, liver, kidneys, and blood.
• Steroids and Other Sports Drugs (PEDs): substances used to enhance athletic performance.
  • Includes: anabolic-androgenic steroids; stimulants; HGH; hCG; herbal and nutritional supplements; some therapeutic drugs (painkillers, beta blockers, diuretics).
  • Physical effects: increased muscle mass and strength; long-term use can cause acne, high blood pressure, testicular atrophy in men, masculinization in women.
  • Mental effects: stimulant-like highs, increased confidence, possible aggressive behavior (roid rage).
• Psychiatric Medications: used to rebalance brain chemistry in mental illness, addiction, etc.
  • Common classes: antidepressants (Celexa, Prozac, Luvox, Zoloft, Paxil, Cymbalta, Pristiq); antipsychotics (Seroquel, Risperdal, Abilify, Haldol, Zyprexa); antianxiety drugs (Xanax, Buspar, Lyrica off-label; panic disorder meds like Inderal).
  • Trends: pharmacology has expanded as an alternative to psychotherapy for many conditions; despite stable overall psychiatric disorder incidence, more drugs exist and are prescribed.

Five Historical Themes of Drug Use (Key Global Patterns)

• Theme 1: People use psychoactive drugs and behaviors to cope with environment and to enhance existence; use has a purpose linked to social context.
• Theme 2: Brain chemistry can be altered by drugs and behavioral addictions, producing altered states of consciousness; effects vary by drug and individual.
• Theme 3: Ruling classes, governments, industry, and criminal organizations have historically been involved in growing, manufacturing, distributing, taxing, and prohibiting drugs.
• Theme 4: Technological advances (refining, synthesizing, manufacturing) increase potency and delivery efficiency, intensifying effects and addiction risk.
• Theme 5: Delivery methods (smoking, injecting, ingesting, vaporizing) have evolved to increase rapidity and magnitude of effects, shaping patterns of use and abuse.
• These themes recur across centuries and cultures, underscoring why policy, treatment, and education must adapt with societal and scientific changes.

Historical Timeline: Prehistory to Modern Times (Selected Highlights)

• Prehistory and Neolithic (8500–4000 BC):
  • Roughly 4,000 psychoactive plants exist; about 60 are commonly used.
  • Early evidence of psychoactive plant use dates back to hunter-gatherer societies; shamanistic practices linked to drug-induced altered states.
  • Shamans acted as healers, exorcists, and mediators with the supernatural, using both natural and drug-induced means.
  • Use spread through tribal migrations.
• Ancient Civilizations (4000 BC–AD 400):
  • Alcohol: widely used; beer and wine production tied to religion and social life.
  • Opium: cultivated with opium poppy; used medicinally and for sedation/euphoria; named hul gil by Sumerians (the plant of joy).
  • Cannabis: cultivated for oil, fiber, seeds, medicinal, and psychedelic properties.
  • Mesopotamian and Egyptian pharmacology recorded opium and cannabis uses; heroin and morphine later tied to opium derivatives.
  • Mesopotamian tablets (Sumer) document alcohol as a solvent for opium; biblical and ancient texts reference alcohol in religious and social contexts.
• The Middle Ages (400–1400):
  • Psychedelic hexing herbs (nightshade family): datura, belladonna, mandrake; used in medicine and ritual, later linked to witchcraft accusations.
  • Ergot mold (Claviceps purpurea) on rye produces lysergic acid derivatives; ergotism outbreaks documented; Saint Anthony’s fire as a historical label.
  • Theophrastus described datura as medicine, psychedelic drug, and poison depending on dose; dose-dependent effects widely observed historically.
• Renaissance and Age of Discovery (1400–1700):
  • Distillation and refinement of alcohol; opium therapy re-emerges in medical practice.
  • European exploration disseminates tobacco, coca, coffee, tea, cacao; coca trade and opium trade expand globally.
  • Alcohol laws and temperance movements emerge; religious and moral considerations influence regulation.
• The Enlightenment and Early Industrial Revolution (1700–1900):
  • Refinement and new delivery methods (hypodermic needles) increase abuse potential.
  • Distilled spirits (gin) led to epidemics (London Gin Epidemic, 1710–1750) and heavy taxation/regulation attempts.
  • Coffee, tea, and chocolate spread globally; quinine-based medicines and new pharmacologies grow.
  • The opium trade intensifies in China; Opium Wars (1839–1842, 1856–1860) shape global geopolitics and colonial commerce.
• The 20th Century to Present:
  • Regulation and scheduling: Pure Food and Drug Act (1906); various controls on opium and narcotics; 1914–1920s prohibition in various locales; Volstead Act; Prohibition era in the US (1920–1933).
  • Substantial growth in pharmaceutical industry, prescription drug use, and later prescription drug abuse (opioids, benzodiazepines, etc.).
  • DSM-5 and Mental Health Parity/ Addiction Equity acts shape the diagnosis and treatment of substance-use and behavioral addictions.
  • 1980s–present: emergence of club drugs, synthetic cannabinoids and stimulants, methamphetamine epidemics, crack cocaine waves, and evolving global trafficking networks.

Delivery, Pharmacology, and Drug Potency (Technologies and Trends)

• Potency and delivery:
  • Potency increases with refined production (e.g., street cocaine often 60–70% cocaine content vs coca leaf 0.5–2%).
  • Faster delivery methods (injection, crack cocaine, inhalation) accelerate onset and addiction risk.
  • Technological advances include vaping nicotine, vaporizing alcohol (emerging), and electronic cigarettes.
• Potency and addiction:
  • Higher potency correlates with faster addiction development and greater health risks.
• Examples of delivery evolution:
  • Coca leaf chewing (coca paste) vs refined cocaine delivery methods; morphine injection vs oral use; crack cocaine vs powder cocaine; opiate injection and heroin use patterns.

Notable Historical Examples by Substance

• Opium (and morphine/heroin):
  • Early medicinal use; in the 19th century heroin marketed by Bayer as a cough remedy and later recognized for higher addiction liability; heroin use spread worldwide in the 20th century.
  • Methods of use evolved: opium smoking (China, 1500s); ingestion; hypodermic injection after 1855 (Alexander Wood); adulteration and combinations with alcohol or other substances.
• Coca and Cocaine:
  • Coca leaves used for stamina, altitude adaptation, and ritual/social use in the Andes; coca tax and trade by colonizers; cocaine refined and used in patent medicines; Coca-Cola historically contained cocaine until the early 20th century.
  • The rise of illicit cocaine trade and cartel dynamics in the late 20th century; globalization of drug markets.
• Cannabis (Marijuana):
  • Ancient use in medicine and ritual; US prohibition campaigns in the 1930s; LaGuardia Committee (1938–1941) found marijuana not addictive to compare with morphine, though that report was contested and ignored for political reasons.
  • Sinsemilla cultivation and rising THC potency in the late 20th century; modern debates about medical and recreational use across states.
• Alcohol, Coffee/Tea, and Chocolate (Caffeine):
  • Alcohol: from ancient religious to social/industrial regulation; temperance movements; Prohibition in the US; later regulation and taxation.
  • Coffee/Tea/Chocolate: global spread; caffeine identified in 1819 (Runge); socialization through coffeehouses and tea ceremonies; chocolate valued as a stimulant.
• Psychedelics and Hallucinogens:
  • Mescaline (mescal beans, peyote); psilocybin mushrooms; amanita muscaria; ergot/ergotamine linked to LSD; Soma in Vedas; ceremonial uses in Mesoamerica; psilocybin mushrooms widely used in pre-Columbian and modern times.
  • LSD discovered in 1938 (Hofmann, Sandoz) and its mid-20th-century prominence; MDMA (ecstasy) and other synthetic psychedelics emerged in the 1960s–1980s.
• Inhalants and other substances:
  • Inhalants include solvents, nitrates, and nitrous oxide; risks include delirium and respiratory depression.
• Anabolic steroids and PEDs:
  • Widely used in sports to increase muscle mass and performance; long-term risks include aggression, liver problems, and cardiovascular issues.
• Psychiatric Medications and Neurochemistry:
  • Antidepressants, antipsychotics, anti-anxiety medications; the rise of psychopharmacology as a predominant treatment approach; dual diagnosis (co-occurring mental illness and substance-use disorder) becomes a critical area of study and treatment.

Modern Policy, Regulation, and Institutional Frameworks

• Early 20th century regulation:
  • Pure Food and Drug Act (1906) restricted misbranding and adulteration; opium and morphine became more controlled later.
  • 1909 Opium smoking exclusion/ regulation and general restrictions on narcotics.
• 20th-century reform and enforcement:
  • 1970 Comprehensive Drug Abuse Prevention and Control Act (Controlled Substances Act) established five schedules based on abuse potential, medical use, and public health risk.
  • Schedule I: high abuse potential with no approved medical use (e.g., heroin, LSD, peyote, psilocybin, mescaline, MDMA, cannabis).
  • Schedule II–V: progressively lower abuse potential with medical uses (e.g., cocaine, meth, morphine; benzodiazepines; certain OTCs).
• Recent regulatory trends:
  • 1984–2010s: criminal justice reforms, drug courts, and expansion of treatment-based approaches for first-time offenders; debates about legalization, decriminalization, and medical marijuana.
  • 2010s–2020s: movement toward medicalization of addiction, expanded insurance parity for mental health and addiction treatment, and ongoing debates about scheduling and precursor regulation.
• Health policy and public health:
  • DSM-5 (2013) redefines addiction and behavioral addictions under a broad umbrella (Substance-Related and Addictive Disorders); ICD-10 remains widely used in many countries.
  • Mental Health Parity and Addiction Equity Acts (1996, 2008) aim to treat mental health and addiction as medical illnesses with parity in insurance coverage; full implementation has faced regulatory and cost challenges.
• Global health concerns:
  • HIV/AIDS, hepatitis C, and other infectious diseases intersect with injection drug use; public health strategies increasingly emphasize harm reduction alongside treatment and prevention.
• Sports and anti-doping:
  • World Anti-Doping Agency (WADA) coordinates global anti-doping efforts; testing, physiology, and blood profile monitoring (e.g., abnormal hematocrit) are used to detect PED use beyond direct drug testing.
• Behavioral addictions and new frontiers:
  • Gambling, internet gaming, social media, and online behaviors recognized as potential addictions; DSM-5 includes Gambling Disorder; other behavioral addictions are under study with ongoing policy development.
• Tobacco regulation:
  • Surgeon General reports link smoking to substantial morbidity and mortality; global tobacco control efforts include warnings, advertising restrictions, and taxation; e-cigarettes and vaping rise as new delivery systems with regulatory challenges.

Pharmacology and Treatment: Medical Approaches to Addiction

• Dual diagnosis and integrated treatment:
  • Approximately one-third of those with mental illness have a substance-use problem, and one-third of those with substance-use problems have a mental illness.
  • SAMHSA promotes an "any door is the right door" approach to treat dual diagnoses in an integrated system.
• Addiction treatment modalities:
  • 12-step programs (e.g., Alcoholics Anonymous, Narcotics Anonymous) and therapeutic communities.
  • Pharmacotherapies: detoxification, anti-craving medications, long-term maintenance, and relapse prevention.
  • Buprenorphine (Suboxone®, Subutex®) for opioid craving relief; safer than methadone for some patients; can be office-based with naloxone in combination (Suboxone) to deter misuse.
  • Methadone maintenance: effective but costly; buprenorphine is often preferred for office-based treatment.
  • Zubsolv: buprenorphine/naloxone combination tablet for sublingual use.
  • Opioid hyperalgesia and chronic pain management concerns in prescribing practices; hyperalgesia can magnify pain with prolonged opioid exposure, complicating treatment.
• Prescription drug abuse (Generation Rx):
  • A surge in misuse of prescription opioids and benzodiazepines; opioid pain meds and benzodiazepines contribute to emergency department visits and overdoses.
  • Diversion and nonmedical use of prescription drugs contribute to rising mortality; efforts emphasize safer prescribing and monitoring.
• Behavioral/psychological considerations:
  • Motivational interviewing and cognitive-behavioral therapies shown to improve outcomes in some populations.
  • Dual diagnosis treatment requires balancing psychotherapy with pharmacotherapy, considering potential interactions and dependencies.
• Public health and medical considerations:
  • The affordability and access to addiction treatment remain central concerns; policy shifts toward criminal justice reform and treatment-oriented approaches aim to reduce societal costs of addiction.

Current and Emerging Trends in Psychoactive Drug Use

• Club drugs and synthetic products:
  • Ecstasy (MDMA) and related psychedelic stimulants remain popular in club scenes; synthetic cannabinoids (Spice, K2) and synthetic cathinones (bath salts) pose public health challenges due to rapid formulation changes and testing evasion.
  • Kratom and other plant-based products enter markets with evolving legality and safety concerns.
• Opioids and heroin crisis:
  • Declining heroin purity and price fluctuations; synthetic opioids and counterfeit pills complicate public health responses.
  • Buprenorphine/Naloxone combinations and office-based treatments expand access to care but face regulatory and reimbursement challenges.
• Cannabis policy and markets:
  • Legalization for medical and/or recreational use in multiple jurisdictions; ongoing debates about potency, synthetic cannabinoids, and public health impacts (including risk of dependence and hyperemesis syndrome in heavy, chronic users).
• Internet, gaming, and digital addictions:
  • Behavioral addictions such as online gambling, video gaming, social media use, and smartphone dependence are increasingly recognized in clinical and policy discussions.
• Global health and geopolitics:
  • Ongoing opium production in Afghanistan; cocaine and heroin dynamics in Latin America and Asia; insurgent and state actors using drug economies to finance activities; ongoing efforts to curb production and trafficking.
• Public health innovations:
  • Neuroimaging advances (DTI, diffusion spectrum imaging, PET, fMRI) enhance understanding of addiction and treatment targets.
  • Epigenetics and gene-sequencing approaches reveal genetic contributions to vulnerability and resilience; potential for personalized medicine in addiction treatment.
• Societal and cultural shifts:
  • Shift from supply-reduction to demand-reduction strategies; drug courts expand access to treatment for offenders; stigma reduction supports recovery efforts.
• Major societal health concerns:
  • Estimated worldwide burden of alcohol, illicit drugs, and tobacco use; clubs and social contexts continue to drive experimentation in youth and adults alike.

Quantitative Highlights (Key Numbers, in LaTeX)

• Global and societal impact estimates (as cited in the text):
  • Approx. $2 imes 10^{9}$ people drink alcohol.
  • Approx. $7.6 imes 10^{7}$ people have an alcohol use disorder.
  • Approx. $1.67 imes 10^{8}$ to $3.15 imes 10^{8}$ people use illicit drugs.
  • Approx. $1.1 imes 10^{7}$ to $2.1 imes 10^{7}$ people inject drugs.
  • Approx. $1 imes 10^{9}$ people use tobacco.
  • Approx. $1.80 imes 10^{8}$ people smoke marijuana each year.
• Substance potency comparisons:
  • Coca leaves contain caste of cocaine: 0.5 ext{%} ext{ to } 2 ext{%} cocaine by weight; street cocaine purity commonly 60 ext{%} ext{ to } 70 ext{%}.
• Historical outcomes and policy effects:
  • The Gin Epidemic (early 18th century) led to revenue-focused regulation rather than prohibition, illustrating how tax and regulation shape consumption.
  • Prohibition era (1920–1933) in the U.S. reduced public drunkenness but spurred organized crime and illicit markets; after repeal, social patterns shifted but addiction persisted.
• Notable drug potency shifts:
  • Modern marijuana potency up to 14× higher in some cases than 1970s street cannabis; potency trajectories affect addiction risk and health outcomes.

Quotes and Metaphors (Illustrative Touchstones)

• Hoover (1928): Prohibition as a great social and economic experiment.
• FDR (1932): Repeal of Prohibition and beer as political symbol.
• Nixon (1971): War on Drugs and the importance of supply-side and demand-side strategies.
• Reagan (1982): Emphasis on fighting illegal drugs in the U.S.
• Other reflections emphasize the evolving political and cultural climate surrounding drug policy.

Ethical, Philosophical, and Practical Implications

• Balancing treatment and punishment: shifting emphasis toward treatment (e.g., drug courts) requires addressing social determinants, accessibility, and stigma.
• medicalization vs. psychotherapy: increasing reliance on psychiatric medications raises questions about over-reliance on pharmacology vs. psychotherapy and behavioral interventions.
• Dual-diagnosis and integrated care: need for systems that adequately address co-occurring mental illness and substance-use disorders.
• Public health vs. civil liberties: debates about legalization, taxation, and regulation must balance public health benefits with personal freedoms.
• Equity and access: disparities in treatment access, funding, and outcomes require deliberate policy design to avoid widening health inequities.

Key Takeaways and Connections to Foundational Principles

• The history of psychoactive drugs shows a consistent pattern: discovery, ritual/medical use, broader social adoption, regulation, and shifts in use and abuse driven by technology and culture.
• The brain’s reward circuitry underpins craving, addiction, and relapse, linking pharmacology to behavior and social context.
• Modern policy emphasizes a blend of prevention, treatment, and regulation (harm reduction, pharmacotherapy, drug courts, and mental health parity) to address diverse consequences of drug use.
• Behavioral addictions (gambling, internet use, gaming, eating disorders) are increasingly recognized as part of the addiction spectrum, highlighting shared neurochemical pathways with substance-use disorders.

Connections to Foundational Principles (Neuroscience and Public Health)

• Neurochemistry: brain chemicals (dopamine, serotonin, GABA, norepinephrine) interact with drugs and psychiatric medications to shape mood, motivation, and behavior.
• Public health ethics: balancing individual autonomy with societal protection; evidence-based policy keeps pace with science and social norms.
• Pharmacology-to-treatment bridge: understanding drug mechanisms informs safer prescribing, harm-reduction strategies, and effective relapse prevention.

Glossary of Selected Terms (quick-reference)

• CNS: central nervous system
• VTA: ventral tegmental area
• MDMA: 3,4-methylenedioxymethamphetamine (ecstasy)
• THC: delta-9-tetrahydrocannabinol, main active ingredient in cannabis
• GABA: gamma-aminobutyric acid
• MAOI: monoamine oxidase inhibitor
• DSM-5: Diagnostic and Statistical Manual of Mental Disorders, 5th Edition
• WADA: World Anti-Doping Agency
• PEDs: performance-enhancing drugs
• NA/AA/MA/GA: Narcotics Anonymous, Alcoholics Anonymous, Marijuana Anonymous, Gambling Anonymous

End Notes

• The material presented emphasizes that drug effects, risks, and societal impact are deeply intertwined with historical, cultural, economic, and political contexts.
• Studying the history of psychoactive drugs helps in understanding how current policies, treatment modalities, and social attitudes evolved—and why they will continue to evolve with science and society.